Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02185417 · ClinicalTrials.gov registry record · Phase 3
Diuretic Comparison Project
A Phase 3 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 20,723
- Enrollment target
NCT02185417: Completed Phase 3 study, sponsored by VA Office of Research and Development.
NCT02185417 is a Phase 3 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 20,723 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02185417, a Phase 3 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20,723 participants
- Enrollment target
Study Summary
The Diuretic Comparison Project aimed to evaluate whether chlorthalidone, as compared with hydrochlorothiazide, would reduce the risk of major nonfatal cardiovascular disease outcomes and non-cancer-related deaths in older patients with hypertension who were receiving hydrochlorothiazide at baseline. The investigators incorporated the pragmatic methods used by the Department of Veterans Affairs (VA) Healthcare System to provide a real-world assessment of the effectiveness of chlorthalidone as compared with hydrochlorothiazide in routine clinical care.
Interventions
- DRUG Hydrochlorothiazide (HCTZ)
- DRUG Chlorthalidone (CTD)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20,723 participants |
| Start Date | 2016-06-15 |
| Est. Completion | 2022-12-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02185417
The ClinicalTrials.gov registry entry for NCT02185417 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 20,723 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Hydrochlorothiazide (HCTZ) is the first listed.
NCT02185417 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02185417 about?
NCT02185417 is a clinical study titled "Diuretic Comparison Project". The Diuretic Comparison Project aimed to evaluate whether chlorthalidone, as compared with hydrochlorothiazide, would reduce the risk of major nonfatal cardiovascular disease outcomes and non-cancer-related deaths in older patients with hypertension who were receiving hydrochlorothiazide at baseline...
What is the current status of trial NCT02185417?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 20,723 participants. The study started on 2016-06-15. Estimated completion is 2022-12-29.
What interventions are being tested in trial NCT02185417?
The interventions under investigation include: Hydrochlorothiazide (HCTZ) (DRUG), Chlorthalidone (CTD) (DRUG).
Who is sponsoring clinical trial NCT02185417?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.